<ul>
<li>BridgeBio Pharma director Randal W. Scott cut his direct stake to 11,589 shares in transactions dated May 15.     *      He exercised options to acquire 10,000 shares at USD 16.75, then sold 10,000 shares at prices ranging from USD 66.69 to USD 69.12.     *      Scott also reported 4,000 shares held indirectly through Thinking Bench Capital LLC. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001470831-26-000470), on May 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</li>
</ul>

BBIO

SBIO

LABU

ARKG

<p>BridgeBio Pharma director Randal W. Scott sold USD 655,873 in common shares, reducing his stake to 11,589 shares. He exercised options for 10,000 shares at USD 16.75 and sold them at prices between USD 66.69 and USD 69.12. Scott also holds 4,000 shares indirectly through Thinking Bench Capital LLC.</p>

PUBT

Bridgebio Pharma

iShares Biotechnology ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

BridgeBio director Randal W. Scott sells USD 655,873 in common shares